

**The tables in the "Half-year Report" announcement released on 30 September 2025 at 7am under RNS No 3030B were unclear and accordingly the announcement has been updated so that readers can access the tables via a pdf link now contained in the announcement.**

**All other details remain unchanged.**

**The full amended text is shown below.**

Ovoca Bio PLC  
30 September 2025

**Ovoca Bio plc**  
**("Ovoca" or the "Company")**

**Interim Results for the six months ended 30 June 2025**

Dublin, Ireland, 30 September 2025 - Ovoca Bio announces its interim financial statements and report covering the six-months ending 30 June 2025.

Please click on the following link to view the full Half Year Report and extracts are set out at the end of this announcement:

[http://www.ms-pdf.londonstockexchange.com/ms/4541B\\_1-2025-9-30.pdf](http://www.ms-pdf.londonstockexchange.com/ms/4541B_1-2025-9-30.pdf)

**CEO Statement**

Today we have published Ovoca's financial statements covering the six-month period to the end of June 2025, which I encourage all stakeholders to read. On 7 May 2025 the Company entered into a conditional Letter of Intent ("LOI") to acquire 100% of Tadeen International Limited ("Tadeen"), a UK-registered company, which indirectly owns 100% of a portfolio of mineral exploration licenses in Morocco prospective for Copper and Silver (the "Proposed Acquisition"). The team at Ovoca has been working to complete the Proposed Acquisition and in due course further announcements will be made as we finalize the acquisition of Tadeen.

As at 30 June 2025, the Company had cash and cash equivalents amounting to €1,526 million (1,788 million) and we will continue to carefully manage our financial resources. The costs incurred during the period relate to the costs of work in relation to the Proposed Acquisition along with corporate costs.

I would like to thank the management team of the Company and the Board of Directors for their support.

**End**

For further information:

**Ovoca Bio plc**  
Tim McCutcheon (Chief Executive Officer)  
Tel +353 1 661 9819  
[info@ovocabio.com](mailto:info@ovocabio.com)

**Beaumont Cornish Limited (Nominated Adviser and Broker)**  
James Biddle/ Roland Cornish  
Tel: +44 (0) 207 628 3396

**Nominated Adviser Statement**

Beaumont Cornish Limited ("Beaumont Cornish"), is the Company's Nominated Adviser and is authorised and regulated in the United Kingdom by the Financial Conduct Authority. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other person for providing the protections afforded to customers of Beaumont Cornish nor for advising them in relation to the transaction and arrangements described in the announcement or any matter referred to in it.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IR URRURVSUKOAR